Mineralys Therapeutics, Inc.
Climate Impact & Sustainability Data (2020-12-31 to 2021-12-31)
Reporting Period: 2020-12-31 to 2021-12-31
Environmental Metrics
Climate Goals & Targets
Environmental Challenges
- Limited operating history and no products approved for commercial sale.
- Dependence on the success of MLS-101.
- Need for substantial additional funding.
- Risks associated with clinical and preclinical development.
- Reliance on exclusive license with Mitsubishi Tanabe.
- Potential impact of the COVID-19 pandemic.
- Significant competition.
- Reliance on third parties for clinical trials and manufacturing.
- Potential challenges in obtaining and maintaining intellectual property protection.
Mitigation Strategies
- Securing additional funding through this IPO.
- Strategic partnerships to maximize the value of MLS-101.
- Careful management of relationships with third parties.
- Continued efforts to obtain and maintain intellectual property protection.